SC3: Understanding and Modulating Tumor Microenvironment for Immunotherapy
SUNDAY, MAY 3 | 10:00 AM – 1:00 PM
ABOUT THIS COURSE: This interactive short course tackles our emerging understanding of the role of the tumor microenvironment (TME) in tumor immunotherapy. The TME can have a marked immunosuppressive effect leading to suboptimal responses of tumors to
immunotherapies. Strategies to change the immunosuppressive nature of the TME to one that supports immune responses and enhances the impact of tumor immunotherapy will be discussed.
WHAT YOU WILL LEARN:
- Role of the TME in immune suppression
- Checkpoint inhibitor optimization
- Targeting of regulatory cells
- Reprogramming of immunosuppressive cells
- Modulation of chemokines and cytokines in the TME
- Modification of tumor-reactive lymphocytes to evade the TME
- Combining Standard of Care (RT & Chemo) with Immunotherapy
INSTRUCTOR BIOGRAPHIES
Scott Gerber, PhD, Assistant Professor, Co-Director, Center for Tumor Immunology Research, Surgery, Microbiology, Immunology, Radiation Oncology, University of Rochester Medical Center
Dr. Gerber is a tumor immunologist whose
laboratory focuses on harnessing the immune system to recognize and kill cancerous cells. His lab uses an immunotherapeutic approach to enhance the efficacy of chemo/radiotherapies to control or even cure both primary and metastatic malignancies.
RJ Tesi, MD, CEO, CMO, INmune Bio
After an academic career as a transplant surgeon, RJ Tesi joined industry to develop novel therapies to manipulate the immune system; first focusing on immunosuppression and autoimmunity within
the adaptive immune system and more recently on the innate immune system in cancer and neurodegenerative diseases. Dr. Tesi is the CEO and CMO of INmune Bio, a NASDAQ company (INMB).